Full-Time
Updated on 9/3/2026
AI-powered language services and localization
No salary listed
Mumbai, Maharashtra, India
In Person
Night shift from 8:30 PM to 5:30 AM India time is required.
See people who can refer or advise you
RWS Holdings plc provides language services and technology solutions on a global scale for sectors including aerospace, defense, automotive, life sciences, and more. Its offerings span localization, content management, artificial intelligence, and intellectual property, delivered through AI-powered language services paired with human expertise. Clients engage through service contracts and technology licensing to enable multilingual digital experiences and streamline processes. The company differentiates itself by serving a wide range of industries with tailored, compliant solutions that integrate AI, content management, and IP capabilities under one umbrella. Its goal is to help businesses overcome language barriers and optimize operations across multilingual environments.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Chalfont St Peter, United Kingdom
Founded
1958
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Remote Work Options
RWS has launched M-GATE, an independent benchmark measuring how well 70 AI models handle grammar, translation and efficiency across 30 languages. The benchmark reveals significant blind spots: some leading models score below 50% — worse than random guessing — on grammar tests in certain languages. Google's Gemini 3.1 Pro Preview currently leads overall grammar performance, whilst OpenAI's GPT-5.5 tops translation accuracy. However, no single model excels across all languages. xAI's Grok 4.20 performs best on Fijian grammar, but GPT-5.5 falls below chance on the same language, and Meta's Muse Spark scores just 23%. M-GATE evaluates models using linguist-designed "stumper" sentences and roundtrip translation tests. RWS's CEO Vasagi Kothandapani said the benchmark helps enterprises "choose the right model with confidence" rather than relying on unverified language support claims.
Rockworth's H1 review. With four completed deals announced, and continued buyer appetite for high-quality acquisitions, it's been a strong start to 2026. August 7, 2026 The first half of 2026 has seen continued activity across the mid-market, with high-quality businesses attracting interest from both strategic acquirers and financial investors. At Rockworth, Rockworth Management Partners Ltd has supported clients across a broad range of sectors and transaction types. In this H1 review, Rockworth Management Partners Ltd highlight four successful transactions Rockworth Management Partners Ltd has announced so far this year. These deals demonstrate the range of objectives that can be achieved through a carefully considered transaction, whether that means securing an exit, supporting the next phase of growth, or enabling shareholders to focus on other strategic priorities. Rockworth acted as lead sell-side adviser to the shareholders of legal technology business Obviously on its sale to RWS Holdings plc, a listed AI solutions group. The deal comprises £16.5m of initial cash consideration and up to £23.5m of contingent consideration payable over three years, taking the total potential consideration to £40m. Rockworth acted as lead adviser to the shareholders of Fendequip, a manufacturer of mooring products for superyachts, on its investment partnership with Trusta Industries. Trusta is a UK industrial group with a "buy and own forever" philosophy. The founders will continue to lead Fendequip, with strategic support from Trusta, as the business enters its next phase of growth. Rockworth advised DGL International on the sale of the Craig & Rose brand to Benjamin Moore, the premium paint and coatings company owned by Berkshire Hathaway. The transaction brings together two heritage paint brands and supports Benjamin Moore's international growth ambitions. It also enables DGL International to focus on other strategic priorities across the UK and Europe. Rockworth advised the shareholders of Tolley, a specialist consultancy, on the sale of their business to G&L Scientific Group. Tolley supports pharmaceutical and biotech companies through health technology assessment and reimbursement, including submissions to NICE and the Scottish Medicines Consortium. The management team will continue to lead the business as part of G&L Scientific's expanding group of market access consultancies across Europe. With momentum in M&A continuing into the second half of 2026, Rockworth Management Partners Ltd expect strong businesses with clear growth prospects to remain attractive to both strategic and financial buyers. If you are considering selling your business, securing investment or exploring other strategic options, its team would welcome a confidential, no-obligation conversation about your objectives and the opportunities available Get the latest news from Rockworth, plus guidance on topics including building value, raising investment and selling businesses.
RWS Holdings, a London-listed AI solutions company, has agreed to acquire Acogroup, parent company of language services provider Acolad, for £22.4 million ($26 million) in enterprise value. Total consideration is £40.2 million, including roughly £17.8 million for cash held at closing. Founded in 1995 and headquartered near Paris, Acolad operates across 22 countries in Europe and North America with about 1,200 employees. The company reported revenue of £182 million and adjusted EBITDA of £13 million for the year ending 31 December 2025. Roughly half of Acolad's revenue comes from regulated industries, whilst about 75% derives from localisation services. RWS said the deal would extend its AI platforms to more enterprise clients, particularly in Western Europe. The transaction is expected to close in the first half of RWS's 2027 fiscal year, pending regulatory approvals.
RWS launches new linguistic validation service to significantly reduce clinical trial timelines. New service brings critical eCOA trial services together under one program team to speed global studies. Maidenhead, UK 7/14/2026 9:00:00 AM RWS (AIM: RWS.L), a global AI solutions company, today launched a new tech-enabled eCOA translation and linguistic validation service designed to help pharmaceutical companies, clinical research organizations (CROs) and eCOA providers reduce delays in global clinical trials. The service brings together COA licensing, source validation, multilingual translation, Trados-enabled eCOA migration, intelligent workflows, rater training and dedicated program management under a single, integrated operating model - delivered by one program team with end-to-end governance and a single point of accountability across the entire COA lifecycle.
RWS, a global AI solutions company, has launched a new tech-enabled eCOA translation and linguistic validation service aimed at reducing delays in global clinical trials. The service integrates COA licensing, source validation, multilingual translation, eCOA migration, rater training, and programme management under a single operating model. The new offering addresses delays caused by managing these functions across multiple vendors. A dedicated programme team oversees the entire process, from licensing through to global deployment, providing unified governance and accountability. RWS has expanded its digital health portfolio to include rater training as part of this launch. The company is also investing in AI-powered tools to automate repetitive tasks whilst maintaining scientific rigour and regulatory compliance. RWS serves over 80 of the world's top 100 brands and is headquartered in the UK.